Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase
- 1 December 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (17) , 2635-2642
- https://doi.org/10.1097/00002030-200012010-00002
Abstract
To characterize early and later indices of cellular restoration among HIV-1 infected persons treated with abacavir and one protease inhibitor and to identify predictors of CD4 cell increases. Flow-cytometric analyses of lymphocyte phenotypes among 71 antiretroviral treatment naive adults in a 48 week treatment trial. During the first 4 weeks of therapy, increases in naive and memory CD4 cells and in B cells were seen; naive CD8 cells increased while CD8 cells remained stable as memory CD8 cells decreased. During the second phase total CD4 and naive CD4 and CD8 cells increased while total CD8 and memory CD8 cells decreased. The numbers of CD4 cells that expressed CD28 increased from a median of 308 × 106/l at baseline to 477 × 106/l at week 48. Higher baseline plasma HIV-1 RNA levels predicted the magnitude of early CD4 (r = 0.35;P = 0.01), memory CD4 (r = 0.38;P = 0.001) and CD28 CD4 cell (r = 0.29;P = 0.01) restoration but was not related to second phase changes. Younger age predicted a greater second phase (but not first phase) increase in naive CD4 cells (r = −0.31;P = 0.03). Higher baseline levels of HIV-1 replication determine the magnitude of first phase CD4 cell increases after suppression of HIV-1 replication. Second phase (primarily naive) CD4 cell increases are not related to HIV-1 replication but are inversely relate to age suggesting that thymic potential is a major determinant of long term cellular restoration in HIV-1 infected persons receiving antiretroviral therapy.Keywords
This publication has 29 references indexed in Scilit:
- Effect of HIV on Thymic Function before and after Antiretroviral Therapy in ChildrenThe Journal of Infectious Diseases, 2000
- Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimenAIDS, 2000
- Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus LoadThe Journal of Infectious Diseases, 1999
- Potent Antiretroviral Therapy of Primary Human Immunodeficiency Virus Type 1 (HIV‐1) Infection: Partial Normalization of T Lymphocyte Subsets and Limited Reduction of HIV‐1 DNA Despite Clearance of Plasma ViremiaThe Journal of Infectious Diseases, 1999
- Tumor Necrosis Factor (TNF) System Levels in Human Immunodeficiency Virus–Infected Patients during Highly Active Antiretroviral Therapy: Persistent TNF Activation Is Associated with Virologic and Immunologic Treatment FailureThe Journal of Infectious Diseases, 1999
- Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count?AIDS, 1998
- In vivo analysis of Fas/FasL interactions in HIV-infected patients.Journal of Clinical Investigation, 1998
- Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects.Journal of Clinical Investigation, 1997
- A Prospective Study of Human Immunodeficiency Virus Type 1 Infection and the Development of AIDS in Subjects with HemophiliaNew England Journal of Medicine, 1989
- Survival with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1987